ArticleOphthalmology and therapy2024

Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan.

Yasuo Yanagi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.